PharmaDossier
Manufacturing

Drugs Exposed to Flood or Fire: Segregate Them Before a Salvage Decision

How quality teams map flood or fire exposure to stock, packaging and separate laboratory and premises evidence before a commercial drug-salvage decision.

Ran Chen
Ran Chen
13 min read · Published · Source-cited

Start with a hold and the actual exposure question

After a flood or fire affects a pharmaceutical warehouse or distributor, identify potentially affected stock and keep it under the firm’s controlled hold arrangements while the quality unit reconstructs exposure. Segregation is the protective operating approach used in this article. It preserves control during assessment; it does not establish that any stock is suitable for salvage.

The decision starts with 21 CFR 211.208. It addresses improper storage including extremes in temperature, humidity, smoke, fumes, pressure, age or radiation resulting from disasters, fires, accidents or equipment failures. Drug products subjected to the specified improper storage conditions must not be salvaged and returned to the marketplace. Where exposure is uncertain, the section requires both laboratory evidence of conformity with applicable identity, strength, quality and purity standards and premises-inspection evidence that the products and associated packaging were not subjected to improper storage. Appearance supplies supplemental evidence only. 21 CFR 211.208.

A disaster at an address does not, by itself, establish what happened to every unit held there. Equally, an intact carton does not resolve an unknown exposure history. The practical task is to connect the event to identified stock, its location and packaging, then show what each evidence record actually covers. This guide organizes that work for US pharmaceutical quality, warehouse and supply-chain teams.

Section 211.142 requires written warehousing procedures, including quarantine before quality-unit release and appropriate storage conditions. It does not prescribe this article’s detailed response to potentially affected, previously released stock. Section 211.22 gives the quality unit approve-or-reject responsibilities, including for contract-held products. The worksheet below supports that assessment without replacing the firm’s procedures or authorizing release. 21 CFR 211.142(a)–(b). 21 CFR 211.22(a)–(d).

Separate established improper storage from uncertain exposure

Keep the prohibition and the uncertainty provision distinct. Later testing is not an exception for stock already established to have undergone the improper storage addressed by 211.208. For uncertain exposure, a laboratory result cannot supply the premises conclusion, and premises evidence cannot supply laboratory conformity. Both questions remain visible even when one appears easier to answer. 21 CFR 211.208. FDA returned and salvaged-drug Q&A, question 1.

Assessment stateWhat followsWhat remains to document
Established improper storageNo salvage and return to the marketplace under 211.208.Identify the affected stock and retain the actual disposition record.
Exposure uncertain; evidence incompleteThe conditions for salvaging have not been established.Show the laboratory and premises gaps separately; maintain control while the quality unit assesses the record.
Evidence offered to exclude the specified conditionsAssess its coverage for the identified products and associated packaging.Do not treat a worksheet status or an apparently unaffected zone as automatic release authorization.

These assessment labels are editorial aids, not regulatory classifications. A missing record means a question remains unanswered; it does not establish that no useful record can ever be recovered. For example, a missing logger file should trigger a precise request and an assessment of available evidence. The cited section does not require a particular logger technology or make one missing file a universal destruction rule.

The FDA industry Q&A is expressly labeled nonbinding. Its first answer recommends caution and reconstruction of supply-chain and exposure history. Distinguish those recommendations from the regulation’s conditions, and distinguish both from the additional worksheet fields suggested here. Section 211.208 prohibits marketplace salvaging after established improper storage; it does not specify an incineration method or a witnessing procedure. FDA Q&A, question 1. 21 CFR 211.208.

Map the event to premises, lots and packaging

Start with the event footprint, rather than assuming a lot number describes a single exposure history. The same lot may have stock at different premises or in different zones. Use a separate assessment entry wherever a location, presentation or relevant history differs. In this article, “stock group” means that identified portion of stock; it is an organizational term, not an FDA category.

FDA recommends obtaining supplier and distributor names and addresses, identifying potentially affected lots, and determining the exposure’s time frame, duration, nature, scope and location. Its recommendation also calls attention to consequences such as power disruptions and obtaining certification about improper storage. The following mapping steps apply those recommendations; the layout and record-link conventions are editorial. FDA Q&A, question 1.

  • Locate the stock: identify the product and lot, holding entity, premises address and relevant zone. Add packaging presentation and quantity to make the entry traceable. If the precise location is unknown, record that gap rather than assigning all stock to a convenient address.

  • Bound the event: state what happened, where it occurred and the period being assessed. Distinguish the incident period from any later interruption in storage control. Where power disruption matters, request the relevant records without assuming that an outage proves a particular temperature or exposure.

  • Connect the history: link each statement to a document, observation or responsible record holder. Identify movements between locations during the event window. Show when a record covers only part of the period or only a different stock group.

  • Keep upstream premises visible: a statement about the receiving warehouse cannot describe an earlier distributor’s storage history unless its scope actually includes that history. Request the relevant supplier or distributor records and show what remains unknown.

A useful history entry has three parts: the statement, its evidence reference and its limit. For instance, a location record may show where stock was staged at dispatch while leaving its earlier location unresolved. Enter the earlier interval as a gap. This prevents an administrative record from appearing to prove environmental conditions it never recorded.

Treat packaging observations with the same precision. Separate what is observed about the drug product, immediate container and closure, and outer packaging where relevant. Do not convert “no visible damage” into “not exposed.” A photograph can document appearance at a particular time; the assessment still needs the history and premises conclusion relevant to that stock.

Build the condition and container evidence assessment

The worksheet is an editorial synthesis of 211.208, FDA’s question 1 recommendations, quality-unit responsibilities and warehouse controls. It is not an FDA form, validated SOP, laboratory protocol or release algorithm. Its purpose is to expose missing evidence and make the coverage of each record reviewable. 21 CFR 211.208. FDA Q&A, question 1. 21 CFR 211.22. 21 CFR 211.142.

Use a linked context entry and evidence entry for each stock group. The first table defines the context fields; the next preserves separate laboratory and premises columns. Record an evidence reference and an unknown or limitation beside each history item. An empty space should remain an explicit question, rather than silently becoming an acceptable condition.

Context fieldWhat to enter or requestSource status
Product and lotProduct name and lot number; add presentation and quantity to define the stock group.211.208 names product name and lot in its records requirement. Presentation and quantity are suggested supporting fields.
Holding locationSupplier/distributor name and address; relevant premises and internal zone; evidence reference and location gap.FDA Q&A recommends names, addresses and exposure location. Zone layout and reference fields are editorial.
Event historyNature, scope, time frame and duration; relevant power disruption; source reference and uncovered interval.FDA Q&A recommendations. The table does not set a required recording interval.
Condition and packagingSeparate observations of product, immediate container/closure and outer packaging where relevant; record observer and scope.211.208 includes associated packaging in the premises condition. Layer-specific columns and observer fields are editorial.
Supplier certificationStatement reference; which lots, premises, packaging and period it covers; omissions or conflicts.FDA Q&A recommends certification. The coverage questions are editorial implementation suggestions.
Assessment and dispositionQuality-unit assessment reference, unresolved gaps, next-record owner and actual disposition reference.211.22 supports quality-unit responsibilities; 211.208 names disposition records. Owners and reference layout are editorial.

Certification needs a defined scope. If a supplier’s statement identifies the lot but omits the premises or event period, record that omission and seek clarification. Do not extend it to unmentioned locations or packaging. Certification contributes to the history; it does not remove the separate evidence conditions for uncertain exposure.

The following single-row layout is a blank assessment template, not a completed inspection. Link its stock-group reference to the context entry above. Repeat it for another location or presentation when the history differs. Keep the underlying documents available so a reviewer can inspect scope rather than relying on a summarized status.

Stock-group referenceLaboratory evidence and scopePremises evidence and conclusionGap and record ownerQuality assessment and disposition
Product/lot + premises/zone + presentation; link context entry.Report reference; applicable standards; stock covered; limitations or missing evidence.Inspection reference; products and associated packaging covered; relevant period; conclusion and limitations.Unanswered question; evidence requested; responsible record holder.Quality-unit assessment reference; unresolved questions; actual disposition reference when determined.

Read across the row before drawing a conclusion. Does the laboratory record cover the stock identified in the context entry? Does the premises inspection address both product and associated packaging for the relevant location and event? Does a supplier statement cover the same period? A complete-looking row with mismatched references still leaves the underlying question unanswered.

Maintain a separate gap statement for each mismatch. “Premises history incomplete” is less useful than “the referenced inspection does not address the upstream holding period.” The latter identifies the question the next record must answer. Assigning an owner makes follow-up practical; it does not transfer approve-or-reject responsibility away from the quality unit.

Show what a missing evidence record changes

The following examples are wholly fictional illustrations of record coverage. They contain no measured exposure values, laboratory results or findings about real stock. They demonstrate how the worksheet organizes questions; none concludes that a lot is safe to release.

Group A: improper storage is established

An identified group at the affected premises has documented improper storage of the kind addressed by 211.208. Record the product, lot, location and evidence establishing that finding. The group cannot enter a salvage-to-market route. Neither a later photograph of intact containers nor a proposal to test samples changes that branch. Record the actual disposition through the firm’s applicable procedures; this illustration prescribes no destruction technique. 21 CFR 211.208.

Group B: another zone has an unresolved history

Stock sharing the lot number was held in another zone. Its cartons appear normal, but the available premises record does not cover the full relevant event period. Do not borrow Group A’s history or presume that distance from the event proves nonexposure. Identify the uncovered interval and request evidence relevant to that zone. Keep the laboratory evidence question separate. Until the required evidence is established, the uncertainty conditions have not been met.

Group C: an upstream statement has incomplete coverage

A distributor provides a statement about stock held upstream. It names a product and lot but does not identify the holding address or the period covered. Enter the statement reference and those omissions. Request clarification and the relevant premises history; keep any laboratory evidence separately identified. The statement cannot be stretched into a conclusion about all stock movements, and a later receiving photograph cannot reconstruct the missing upstream period.

Fictional groupLaboratory columnPremises columnAssessment gap or boundary
A: established improper storageA proposed assay does not override the prohibition.Reference establishing improper storage for this group.No marketplace salvage; retain actual disposition.
B: uncertain exposure in another zoneRecord applicable evidence and scope, or mark missing.Event-period coverage is incomplete.Request the missing zone history; no release conclusion.
C: incomplete upstream statementRecord separately; certification is not laboratory evidence.Address and period are not established by the statement.Clarify scope and obtain relevant premises evidence.

These examples separate three different outcomes of review: an established prohibition, an unanswered location history and an inadequately scoped supplier statement. Treating all three as the same paperwork failure would hide what the quality unit actually needs to assess. Treating any as a passing worksheet would hide the unresolved safety question.

Keep appearance and laboratory scope in proportion

Section 211.208 limits organoleptic examination to supplemental evidence of conformity with the relevant identity, strength, quality and purity standards. Appearance and other sensory observations can be recorded, but they cannot replace either evidence condition for uncertainty. Describe what was observed and its scope without upgrading it to a claim that an intact package protected its contents. 21 CFR 211.208.

The regulation does not supply a universal disaster test panel, sample count or acceptable exposure limit. Identify the applicable standards and the scope of the laboratory evidence rather than copying a list of assays from another product. A report’s existence is not enough: the quality-unit assessment needs to address what it establishes for the stock under review. This worksheet selects no methods and supplies no numerical acceptance criteria.

Likewise, the premises column calls for the inspection evidence specified in 211.208, not a universal checklist of sensors or engineering studies. Record which products, associated packaging, locations and period the evidence addresses. If a file is missing, state the unanswered question and assess the available record; do not claim that a particular technology is mandatory under this section.

Under 211.22(b), adequate laboratory facilities must be available to the quality unit. Paragraph (c) addresses its approval or rejection of procedures and specifications affecting product quality; paragraph (d) addresses written responsibilities and procedures. Those provisions support accountable assessment. They do not permit the quality unit to waive the salvaging conditions. 21 CFR 211.22(b)–(d).

Record the assessment without creating a release shortcut

Section 211.208 requires records including product name, lot number and disposition. Link that identity to the evidence reviewed and the actual decision. The additional references, scope notes and owners proposed here help a later reviewer follow the reasoning; they are not an expanded list of fields expressly named in the section. 21 CFR 211.208.

Check that the conclusion covers only the identified stock group. If evidence describes one premises, do not silently apply it to stock with a different holding history. If new information changes the assessed scope, make the relationship between the earlier entry and the revised assessment clear through the firm’s procedures. The worksheet should preserve the question and evidence behind the outcome, rather than merely accumulate completion marks.

Keep commercial returns in their own regulatory context. Section 211.204 requires returned products to be identified and held and provides separate conditions and records. Calling disaster-affected stock a return does not bypass 211.208. The detailed returns workflow is covered in the linked guide, while this assessment starts with the event and the stock locations. 21 CFR 211.204. 21 CFR 211.208.

For the returned-lot decision and its distinct record requirements, see Returned Drug Lots: When to Reprocess or Destroy Under CGMP. For the separate access and replacement workflow, see Cold-chain excursion workflow for specialty pharmacy replacement drug. Neither workflow supplies the missing disaster evidence for an identified stock group.

FDA’s consumer disaster page concerns the use of medicines affected by fire, flooding, unsafe water or power outages, including a narrow lifesaving-drug emergency exception. That personal-use context does not authorize commercial marketplace salvaging. Keep it separate from the Part 211 assessment rather than importing an appearance-based emergency exception into inventory disposition. FDA: Safe Drug Use After a Natural Disaster. 21 CFR 211.208.

Sources

The eCFR is authoritative but is not the official legal edition of the CFR. The linked Title 21 pages displayed currency through November 9, 2026 when reviewed on November 12. FDA’s industry Q&A contains nonbinding recommendations. The worksheet and fictional illustrations are editorial applications of these sources, not agency forms or inspection results.

Ran Chen
Contributing Editor
Ran Chen

Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.

Follow on LinkedIn →